Drug Profile
Research programme: hepatitis C therapeutics - Digna Biotech/HepaCyl
Alternative Names: InterapoLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Digna Biotech
- Class Interferons
- Mechanism of Action Immunostimulants; Interferon alpha stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hepatitis C
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Hepatitis-C in Spain
- 31 Dec 2010 Preclinical trials in Hepatitis C in Spain (unspecified route)